http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 20:34:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html <p class="bwalignc"> <i>- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China</i> </p><p class="bwalignc"> <i>- TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial’s China subpopulation</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+China+NMPA+Approval+of+TIVDAK%C2%AE+%28tisotumab+vedotin+for+injection%29+for+the+Treatment+of+Adult+Patients+with+Recurrent+or+Metastatic+Cervical+Cancer/26618848.html Mon, 08 Jun 2026 20:34:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.24780665 A.50209015 O.00225875 O.00644488 O.16394061 O.20026344 O.22443941 O.34841441 S1GE34 ZLAB